Skip to content
Screener

Dianthus Therapeutics DNTH Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$13.61K-99.9%
Vor Biopharma logo
Vor BiopharmaVOR
$2.94M-90.5%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.07M+36.3%
TG Therapeutics logo
TG TherapeuticsTGTX
$9.05M+4.3%
Annexon logo
AnnexonANNX
$25.43M-10.2%
Alumis Inc. logo
Alumis Inc.ALMS
$35.66M+1,881%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Thereafter54
Total undiscounted operating lease payments1,654
Less: imputed interest(290)
Present value of operating lease liabilities$1,364
Balance sheet classification:
Current portion of operating lease liabilities$399
Long-term operating lease liabilities965
Total operating lease liabilities$1,364

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's operating lease liabilities (total)?
Dianthus Therapeutics (DNTH) reported operating lease liabilities (total) of $1.36M in Q1 2026.
How has Dianthus Therapeutics's operating lease liabilities (total) changed year-over-year?
Dianthus Therapeutics's operating lease liabilities (total) decreased by 2.3% year-over-year, from $1.4M to $1.36M.
What is the long-term trend for Dianthus Therapeutics's operating lease liabilities (total)?
Over 2 years (2022 to 2024), Dianthus Therapeutics's operating lease liabilities (total) has grown at a -77.7% compound annual growth rate (CAGR), from $29.96M to $1.49M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Dianthus Therapeutics's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude